ncRNAs (non-coding RNAs) are increasingly recognized as critical biomarkers for many diseases. Computational predictions of the most promising disease-associated ncRNAs for biomedical screening are therefore of great importance. The biggest challenge in developing computational approaches for such inference is the integration of data features because of the rich variety of ncRNAs in genome. Moreover, current methods might suffer from the cold-start problem. In order to address the problems, a resource-allocation-based method was presented in this paper to predict disease-associated ncRNAs by incorporating only experimentally supported disease-gene interactions. Potential ncRNAs for a disease of interest were then ranked according to final allocated resource values. When applied to collected datasets for leave-one-out cross-validation on 537 diseases, our approach improved previous methods and demonstrated excellent prediction performance. Case studies on three important diseases suggested most of the top predicted results were validated by independent sources, which showed the usefulness of our method in real situations. Comprehensive prediction results of disease-associated ncRNAs were finally released for future biomedical identification.
I. INTRODUCTION
The Human Genome Project (HGP), an international scientific research collaboration officially launched in 1990 and declared completed in 2003, brought a draft consensus sequence of the euchromatic portion of our human genome with around 3 billion base pairs [1] . Thereafter, another study [2] on a new version (Build 35) of the genome sequence with higher accuracy revealed that there were only 20,000-25,000 protein-coding genes encoded in the genome, which accounted for ∼2% of the whole genome sequence. In other words, most (∼98%) of the human genome did not encode proteins [3] . Therefore, exploring the roles of the vast amount of non-coding RNAs (ncRNAs) would contribute to a more comprehensive and a more complete understanding of human evolution and the causation of complex diseases.
More recently, numerous efforts have been made to detect the functions of ncRNAs through various biomedical advances. For example, Han et al. [4] discovered that hsa-miR-1, a small ncRNA with 22 base pairs, directly targeted the MET gene and down-regulated its expression to inhibit The associate editor coordinating the review of this manuscript and approving it for publication was Wenbing Zhao. gastric cancer cell proliferation and migration by Western blotting and immunohistochemistry. Another research conducted by Hu et al. [5] indicated that knockdown of a long ncRNA entitled AF339813 by siRNA significantly reduced pancreatic cancer cell proliferation and promoted apoptosis.
ncRNAs can be roughly divided into two categories according to their lengths. The ncRNAs in the first category contain short lengths, which include piwi-interacting RNAs (piRNAs), microRNAs (miRNAs) and small interfering RNAs (siRNAs). The ncRNAs in the other category are long non-coding RNAs (lncRNAs), which range from several hundred nucleotides to multiple kilobases in length. Increasing studies have demonstrated that these ncRNAs affect normal gene expressions and contribute to disease progression through a variety of mechanisms. Therefore, the mutations and dysregulations of ncRNAs are linked to a large number of human diseases. Because of their therapeutic potential [6] - [10] , several databases [11] - [15] have been established for curating experiment-supported evidence for miRNA (or lncRNA) and disease associations retrieved from literature.
As experimental identification of disease-associated ncRNAs is time-consuming and costly, computational models VOLUME 7, 2019 This work is licensed under a Creative Commons Attribution 4.0 License. For more information, see http://creativecommons.org/licenses/by/4.0/
[16]- [41] which can provide the most promising predictions of associations between ncRNAs and diseases for further experimental validation have received enormous attention. For example, Chen and Yan [20] devised a semisupervised learning framework with Laplacian regularized least squares for lncRNA-disease association predictions based on lncRNA expression profile. Mørk et al. [23] proposed a scoring system to infer miRNA-disease associations by integrating miRNA-gene interactions and gene-disease associations. Zhong et al. [31] developed a non-negativematrix-factorization-based method for predicting diseaseassociated miRNAs in miRNA-disease bipartite networks with similarity measurement. Pan et al. [39] applied random forest models trained on tissue expression profiles to infer disease-associated lncRNAs. Detailed literal review of computational models to predict potential miRNA-disease associations and lncRNA-disease associations is available at reference [42] and reference [43] , respectively. Reliable inference performance can be obtained from the aforementioned methods regarding miRNA-disease association predictions or lncRNA-disease association predictions. However, there are few methods, as far as we know, presented to comprehensively predict ncRNA-disease associations. We argue that, as a category of regulation factors, it is reasonable to combine short ncRNAs and long ncRNAs for association predictions. Meanwhile, some approaches listed above suffer from the cold-start problem, that of making predictions for a totally new disease whose associated ncRNAs are not available. Finally, choosing informative data features from diseases and ncRNAs and integrating the multiple kinds of information seamlessly for predictions are challenging tasks because ncRNAs are rich in variety.
In this article, we proposed an integrated approach based on resource allocation for relating disease-gene interaction network with disease-associated ncRNAs on a large scale. More specifically, a three-layer gene-disease-ncRNA heterogeneous network, which incorporated experimentally validated disease-gene interactions and disease-ncRNA associations, was first constructed. For a new disease, we used disease genes as features to bridge the gap between existing diseases in the network and the new one. Potentially associated ncRNAs for the new disease were then prioritized according to the values of projected resource. Leave-oneout cross-validation (LOOCV) on 537 collected diseases was conducted to test the inference abilities of our method and we obtained an average AUC value of 0.84. Case studies showed that most of the top predicted results were confirmed by experimental evidence. Comprehensive predictions of ncRNAs for existing diseases were finally made for further biomedical identification.
II. MATERIALS AND METHODS

A. DATASETS
ncRNA-disease associations Currently, several databases, such as miR2Disease [11] , dbDEMC [12] , HMDD [13] , Lnc2Cancer [14] and LncRNADisease [15] , provide information of miRNA-disease associations or lncRNAdisease associations. Among them, HMDD is the most comprehensive database for housing experimentally validated miRNA-disease associations. LncRNADisease is the largest database for integrating experimentally supported lncRNA (and circRNA) and disease associations. In order to enable a large-scale analysis, we downloaded information from the two databases. For miRNA-disease associations in HMDD, records of different miRNA copies that produced the same mature miRNA were merged. We also merged diseases with synonyms and filtered out invalid disease names in the two databases. Redundant records in the two databases were kept only once.
gene-disease interactions Gene-disease interactions were downloaded from DisGeNET [44] , which is a public platform containing one of the largest information of genes associated to human diseases from animal models, expert curated repositories, the scientific literature and so on. Similarly, duplicated gene-disease interactions stored in DisGeNET were taken only once for consideration.
B. METHOD DESCRIPTION
Network Construction Suppose that we have n diseases, m genes and k ncRNAs in the datasets. Let
. . , g m ) represent the gene set and R = (r 1 , r 2 , r 3 , . . . , r k ) indicate the ncRNA set, respectively. The ncRNA-disease associations downloaded from HMDD and LncRNADisease can be modeled as a bipartite network G1 = (D, R, E1), where E1 is the set of edges. An edge is drawn between the disease d i and the ncRNA r j if there exists an association between them. We use a n × k adjacent matrix {a ij } to represent G1, where a ij = 1 if d i and r j is linked, while all other unknown ncRNA-disease pairs are labeled as 0. Similarly, the gene-disease interactions downloaded from DisGeNET can be described as another bipartite network G2 = (D, G, E2), where E2 is the set of edges. A n × m adjacent matrix {b jk } is to represent G2, where b jk = 1 if d j and g k is linked, while all other unlinked pairs are labeled as 0. The two bipartite networks are then integrated into a three-layer gene-disease-ncRNA heterogeneous network.
Predicting associated ncRNAs for a known disease Given the constructed heterogeneous network, our approach to predicting associated ncRNAs for a known disease d k with both gene and ncRNA information is based on the strategy of resource allocation [21] , [45] - [47] . Specifically, the initial resource values of each gene IRV(g i ) and each ncRNA IRV(r j ) for the disease d k are set to be as follows:
IRV (r j ) = 1 if d k and r j is linked 0 otherwise
In the first step, all the resource in both the gene set and the ncRNA set flows equally to the disease set, then the resource FIGURE 1. The steps of resource allocation when predicting associated ncRNAs for a known disease (a) and for a new disease (b). The rectangles, the ellipses and the triangles are denoted as genes, diseases and ncRNAs, respectively. This figure is inspired by reference [47] .
value of each disease in the disease set reads
where W d p is the received resource value of disease d p , D g i is the degree of gene g i and D r j is the degree of ncRNA r j in the heterogeneous network. In the next step, all the resource in the disease set bounds back to the gene set and the ncRNA set, respectively. The resource value for each ncRNA in the ncRNA set is calculated as:
where W r q is the final resource value of ncRNA r q and D d p is the degree of disease d p in the ncRNA-disease bipartite network. An example of the resource-allocation procedure is illustrated in Figure 1(a) . Predicting associated ncRNAs for a new disease Similarly, the initial resource value of each gene for a new disease with gene information but not ncRNA information is set according to equation (1) . In the first step, all the resource in the gene set flows to the disease set, and the resource value in the disease set reads
where W d p is the received resource value of disease d p and D g i is the degree of gene g i in the heterogeneous network.
In the next step, all the resource in the disease set spreads back to the gene set and the ncRNA set, respectively. The final resource value of each ncRNA in the ncRNA set is computed as below:
where W r q is the resource value of ncRNA r q and D d i is the degree of disease d i in the ncRNA-disease bipartite network. An example of the resource-allocation procedure is illustrated in Figure 1(b) . After the final resource allocated to the ncRNA set is calculated, we sort all ncRNAs in the ncRNA set in a descending order according to the resource values. We choose the ncRNAs with the highest values as potentially associated ncRNAs for the disease of interest.
III. RESULTS
A. STATISTICAL ANALYSIS OF THE DATASETS AND THE HETEROGENEOUS NETWORK
In total, 537 diseases had both ncRNA and gene information. For the 537 diseases, we received 14,531 ncRNA-disease associations containing 5924 ncRNAs (826 miRNAs, 350 circRNAs and 4748 lncRNAs) from HMDD and LncRNADisease, and 155,098 gene-disease pairs including 14,642 genes from DisGeNET. The basic statistics of the two sets of data was available at Table 1(a) and Table 1 
(b).
We calculated the degree for each disease in the ncRNA-disease bipartite network and gene-disease bipartite network, respectively. It was discovered that 512 out of the 537 diseases have more degrees in the gene-disease network than in the ncRNA-disease network. This could be explained by the fact that ncRNAs are a relatively new research area and many disease-associated ncRNAs have not been reported in literature yet, which indicated the importance of computational predictions of disease-associated ncRNAs. A whole view of the degree distribution of diseases in the two bipartite networks was available at Figure 2 and Figure 3 , respectively. The two figures showed the two bipartite networks were scale-free.
B. PERFORMANCE EVALUATION
In order to assess the predictive performance of our method, we implemented leave-one-out cross-validation (LOOCV) on the 537 diseases. For each disease, we considered it as a new one and left it out once as the testing data. We kept its disease genes and removed all the associated ncRNAs of the testing disease from our datasets. The remaining 536 diseases with both gene and ncRNA information were taken as the training data. We prioritized the entire ncRNA set for the testing disease according to the allocated resource scores derived from our method.
In each round of testing, we taken the known disease-ncRNA associations for the testing disease as positive instances. For each specific ranking threshold, if the final We used the area under the curve (AUC) value to represent the prediction ability of our method. We finally received an average ROC-AUC value of 0.84 and an average PR-AUC value of 0.1 for the 537 diseases, of which 449 diseases obtained higher ROC-AUC values than 0.7. To be more instructive, we listed each AUC value for the 537 diseases at Supplementary Material S1. The distribution of the 537 ROC-AUC values and PR-AUC values could be seen in Figure 4 and Figure 5 , respectively.
C. CASE STUDIES
In this scenario, case studies on three important diseases (brain neoplasms, lung neoplasms and asthma) were implemented to evaluate the practical performance of our method for inferring disease-associated ncRNAs. In each case study, we treated the disease as a new one with only disease gene information but its associated ncRNAs were unknown and needed to be predicted. VOLUME 7, 2019 As a cause of cancer, brain neoplasms are second only to the disease acute lymphoblastic leukemia for children under the age of 15. It was reported in Australia the average cost of a case of treatment for brain neoplasms is $1.9 million, which is the greatest in all cancers (https://en.wikipedia.org/wiki/Brain_tumor). Therefore, investigating the mechanism of brain neoplasms is of great importance. However the cause of most brain neoplasms is unknown. Among our predicted results, hsa-mir-21 (2 nd in the 5924 ncRNA candidates) was discovered to be associated with the prognosis of patients with brain tumors by a systemic review and meta-analysis of studies [48] . Another study [49] found a strong link between hsa-mir-17 (12 th ) and oncogenesis, including brain tumors. Furthermore, we selected the top 50 predicted ncRNAs and discovered 8 results were supported by literature.
Lung neoplasms are malignant lung tumors characterized by uncontrolled cell growth in lung. Reports suggested that it is the most common cause of cancer-related death in men and second most common in women after breast cancer (https://en.wikipedia.org/wiki/Lung_cancer). We applied our method to this disease for associated ncRNA prediction. We chose the top 50 predicted results from the 5924 candidates and discovered that 33 ncRNAs were confirmed by experimental evidence. For example, a study performed by Gao et al. [50] suggested hsa-mir-21 (3 rd in the 5924 ncRNA candidates) was observed to be upregulated in the squamous cell lung carcinoma tissues compared with normal tissues. Moreover, Munagala et al. [51] demonstrated two miRNAs, hsa-mir-21 (3 rd ) and hsa-mir-155 (4 th ), were found to be significantly upregulated in lung cancer samples and they could be served as promising biomarkers for this disease.
Asthma is a disease which causes repeated episodes of wheezing, chest tightness and breathlessness and affects our lungs (https://www.cdc.gov/asthma/). Asthma and allergic rhinitis (AR) commonly coexist and they are regarded as manifestations of one syndrome with common underlying inflammatory processes. Recent studies have demonstrated the critical role of several ncRNAs in regulating the key pathogenic mechanisms of allergic inflammation. For example, Suojalehto et al. [52] discovered the inappropriate expression of hsa-mir-155 (2 nd ) and has-mir-126 (11 th ) were observed in asthmatic patients compared with controls. In addition, we found 22 out of the top 50 predicted results by our method were supported by experimental evidence.
D. COMPARISON WITH EXISTING METHODS
As we stated in the Introduction section, current methods were specifically developed for miRNA (or lncRNA)-disease association predictions and it was hard to extend these methods and combine various types of ncRNAs for predictions because of the wide variety of ncRNAs and the challenge of integration of data features. Our method enlargeed the scope by incorporating several ncRNAs, including miRNAs, circRNAs and lncRNAs, for predictions, which we thought was an improvement. To the best of our knowledge, our method provided the most comprehensive disease-associated ncRNA predictions.
Previous methods applied various data features, brought by advance in biomedical technology, to predict diseaseassociated miRNAs or lncRNAs. For example, a closelyrelated research by Alaimo et al. [22] used lncRNA-target and target-disease interactions for lncRNA-caused disease predictions. As the authors stated in their paper, current target information for lncRNAs were quite limited, which would restrict the application of their method. Our method did not need to employ ncRNA-target interactions for prediction. We used the information of disease genes to bridge the gap between the known diseases and the new one to predict disease-associated ncRNAs. Different data features used in our manuscript and in other references prevented a direct comparison.
We extended the work of reference [21] into a three-layer heterogeneous network and integrated two more categories of ncRNAs for association prediction. Experimental results from both studies suggested that the incorporation of more experimentally supported association data could improve the prediction performance. Compared with the strategy employed in reference [21] , the information of disease genes was explicitly stated in our manuscript to be features for prediction and results demonstrated excellent inference performance could be achieved using only this kind of features.
It was also worth noting that our method did not need negative samples for prediction. Gold negative data sets were crucial when applying machine-learning-based models for disease-ncRNA association inference. However, negative disease-ncRNA associations were rare because of lack of research interest in biomedical research. Moreover, randomly selected negative samples would produce biased or unstable prediction results.
E. COMPREHENSIVE DISEASE-NCRNA ASSOCIATION PREDICTIONS
After confirming the prediction power of our method, we made comprehensive disease-associated ncRNA predictions. In this inference procedure, we trained our method with both the known interaction information, i.e. gene-disease interactions and ncRNA-disease associations. For each of the 537 diseases, we ranked the potentially associated ncRNAs with respect to their final resource scores and extracted the top 10 predicted results for each disease for further identification. The full list of predicted ncRNAs could be seen in Supplementary Material S2.
IV. DISCUSSION
Biomedical experiments have highlighted the roles of ncRNAs in human diseases. As a large class of non-coding RNAs, ncRNAs are abundant in human genome. Due to the challenge of integration of data features, previous computational methods were separately proposed for miRNA-disease association predictions or lncRNA-disease association predictions. We addressed this problem by incorporating the information of disease genes for comprehensive disease-associated ncRNA prediction. Compared with expression profiles, function annotations or miRNA target genes used in previous models, disease genes applied in our manuscript were more available, which enabled a wider application of our method in biomedical research.The excellent prediction performance of our approach suggests disease genes are one type of critical features in determining disease-ncRNA associations. Since biological studies indicate that ncRNAs may affect normal gene expression levels, diseases could be considered as possible outcomes of such regulations on genes. It should be noted that our current knowledge of disease genes is not complete. Therefore, the results received by our method may be biased and integrating more experimentally-supported disease genes would improve the prediction accuracy of our method.
It is supposed in our method that detailed gene information of a new disease is available, but not ncRNA information. Indeed, this is not practical in a real situation. For example, there is only one gene revealed for the disease African Swine fever in our datasets. However, compared with the newly discovered disease ncRNAs, disease genes are relatively well studied. Another limitation in our method is that we did not exploit any features of ncRNAs. Therefore, for a newly reported ncRNA not in our dataset, we cannot predict its relationships with diseases. Finally, computational predictions of disease-associated ncRNAs provide an effective and inexpensive alternative. Even so, biomedical experiments are an ultimate way for identification.
